REperfusion With Cooling in CerebraL Acute IscheMia II

Inclusion Criteria: * Male or female subjects of any ethnicity and age \>/=18 but \</= 79 years; * Symptom onset \</=8 hours; * Symptoms consistent with an ischemic stroke with a large vessel occlusion (Middle Cerebral Artery (MCA), Internal Carotid Artery (ICA) terminus) as determined by CT imaging of the brain; * Alberta Stroke Program Early CT Score (ASPECTS) of 5-10 on non-contrast CT of the brain; * Ability to undergo endovascular reperfusion therapy; * No contraindications to general anesthesia, conscious sedation, or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated; * A pre-treatment modified Rankin Scale (mRS) of 0 or 1; * Baseline CT scan shows no hemorrhage; * National Institutes of Health Stroke Scale (NIHSS) 14-29; * Subject has either 1) failed iv tissue plasminogen activator (tPA) therapy or 2) contradicted for iv tPA therapy; * Subject is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities. * Subject or legally authorized representative must be able to understand and give written informed consent. Exclusion Criteria: * Females of childbearing potential who are pregnant or not using adequate contraception; * Bleeding diathesis with a platelet count \< 50,000 or International Normalized Ratio (INR) \>1.7 or any active or recent (within 10 to 30 days) hemorrhage; * History of genetically confirmed hypercoagulable syndrome; * Any condition that excludes MRI imaging; * History of dementia, currently on Aricept or Namenda, or other Alzheimer's-like symptoms; * End stage renal disease on hemodialysis; * History of cardiac arrest; * Presence of an inferior vena cava (IVC) filter; * Contrast dye allergy with history of anaphylaxis, known serious sensitivity to contrast agents or any condition in which angiography is contraindicated; * Known allergy to meperidine or buspar; * Prior neurologic event that would obscure interpretation of the signal and current presenting neurologic deficits; * Sustained hypertension (systolic blood pressure (SBP) \> 185 or diastolic blood pressure (DBP) \> 110 refractory to treatment); * Baseline CT/MRI of head showing evidence of mass effect with mid-line shift, hemorrhage, intracranial tumor, arterial vasculitis or dissection, or bilateral stroke; * Presence of any other serious comorbidity that would be likely to impact life expectancy to less than 6 months or limit subject cooperation or study compliance; * Concurrent participation in an investigational clinical study that has not completed the follow-up period or planned participation in another study within the next 3 months; * Any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete, good quality data or the completion of the research study.